Coleman, Morton

selected publications

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood advances. 2019 Academic Article GET IT
Times cited: 12
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. American journal of hematology. 2019 Academic Article GET IT
Times cited: 2
Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. 2018 GET IT
Times cited: 3
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 92
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 7
Oral Lymphomatoid papulosis type C: A diagnostic pitfall, often confused with T-cell lymphoma. 2017 GET IT
Times cited: 3
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 7
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 243
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology. 2016 Academic Article GET IT
Times cited: 33
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood cancer journal. 2016 Academic Article GET IT
Times cited: 46
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Academic Article GET IT
Times cited: 91
Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2016 Review GET IT
Times cited: 25
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016 Academic Article GET IT
Times cited: 47
Biosimilars: Extrapolating the evidence. A roundtable discussion. EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]. 2016 Academic Article GET IT
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 196
It's Time to Take Clarithromycin Seriously in Multiple Myeloma. Acta haematologica. 2015 Editorial Article GET IT
Times cited: 4
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 25
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 12
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Academic Article GET IT
Times cited: 610
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 20
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. 2014 GET IT
Times cited: 126
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 79
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. British journal of haematology. 2014 Academic Article GET IT
Times cited: 66
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 10
Ibrutinib resistance in chronic lymphocytic leukemia. The New England journal of medicine. 2014 Article GET IT
Times cited: 250
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 7
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014 Academic Article GET IT
Times cited: 207
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leukemia research. 2014 Information Resource GET IT
Times cited: 17
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 427
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2013 Academic Article GET IT
Times cited: 130
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 10
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1933
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 30
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 20
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Academic Article GET IT
Times cited: 32
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 19
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 23
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 16
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 33
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 88
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 257
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010 Academic Article GET IT
Times cited: 46
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 46
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 54
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 39
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 43
Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. Oncology (Williston Park, N.Y.). 2010 Academic Article GET IT
Times cited: 7
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Rituximab for thyroid eye disease. Ophthalmic plastic and reconstructive surgery. 2010 Academic Article GET IT
Times cited: 59
Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park, N.Y.). 2009 Review GET IT
Times cited: 16
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. 2009 GET IT
Times cited: 4
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 141
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 254
Progress in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 19
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008 Academic Article GET IT
Times cited: 95
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 48
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 94
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 103
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 107
New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 5
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 50
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 16
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 63
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 32
Persistent and relapsing babesiosis in immunocompromised patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Academic Article GET IT
Times cited: 200
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 53
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 161
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 10
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British journal of haematology. 2007 Academic Article GET IT
Times cited: 79
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. 2007 GET IT
Times cited: 21
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 11
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006 Academic Article GET IT
Times cited: 160
Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?. Cancer. 2006 Academic Article GET IT
Times cited: 10
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 66
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 10
Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clinical lymphoma & myeloma. 2006 Academic Article GET IT
Times cited: 18
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006 Academic Article GET IT
Times cited: 30
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer treatment and research. 2006 Review GET IT
Times cited: 3
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 204
New developments in immunotherapy for non-Hodgkin's lymphoma. Current oncology reports. 2005 Information Resource GET IT
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 139
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 157
The role of mitoxantrone in the treatment of indolent lymphomas. The oncologist. 2005 Review GET IT
Times cited: 48
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 123
CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 161
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 194
Epratuzumab in non-Hodgkin's lymphomas. Current treatment options in oncology. 2004 Review GET IT
Times cited: 12
The role of FDG-PET imaging in the management of lymphoma. Clinical advances in hematology & oncology : H&O. 2004 Review GET IT
Times cited: 28
Epratuzumab: targeting B-cell malignancies through CD22. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Review GET IT
Times cited: 49
CD22-directed monoclonal antibody therapy for lymphoma. Seminars in oncology. 2003 Review GET IT
Times cited: 22
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 225
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in oncology. 2003 Academic Article GET IT
Times cited: 53
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 62
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002 Academic Article GET IT
Times cited: 341
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002 Academic Article GET IT
Times cited: 189
Biology and management of mantle cell lymphoma. Current opinion in oncology. 2001 Information Resource GET IT
Times cited: 48
Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. International journal of radiation oncology, biology, physics. 2000 Academic Article GET IT
Times cited: 3
Primary non-Hodgkin's lymphoma of bone. Cancer investigation. 1998 Editorial Article GET IT
Times cited: 1
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 23
A comparison of survival of patients treated for AIDS-related central nervous system lymphoma with and without tissue diagnosis. International journal of radiation oncology, biology, physics. 1996 Review GET IT
Times cited: 11
Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas. Leukemia. 1994 Academic Article GET IT
Times cited: 9
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 78
Recombinant gamma-interferon has activity in chronic myeloid leukemia. American journal of clinical oncology. 1990 Academic Article GET IT
Times cited: 8
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. American journal of human genetics. 1989 Academic Article GET IT
Times cited: 46
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Leukemia. 1989 Review GET IT
Times cited: 29
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988 Academic Article GET IT
Times cited: 70
Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). International journal of cancer. 1988 Academic Article GET IT
Times cited: 5
The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Seminars in hematology. 1988 Academic Article GET IT
Times cited: 43
Origin of near-haploidy in malignant hematopoietic cells. Leukemia research. 1988 Academic Article GET IT
Times cited: 11
Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer genetics and cytogenetics. 1987 Academic Article GET IT
Times cited: 27
Advances in chemotherapy for large cell lymphoma. Seminars in hematology. 1987 Academic Article GET IT
Times cited: 45
Length polymorphisms of the human Y chromosome in patients with chronic myelogenous leukemia. Cancer genetics and cytogenetics. 1987 Academic Article GET IT
Times cited: 2
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia. Canadian journal of genetics and cytology. Journal canadien de genetique et de cytologie. 1986 Academic Article GET IT
Position of the Y-chromosome at somatic metaphase in patients with chronic myelogenous leukemia (CML). Experientia. 1986 Academic Article GET IT
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 5
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. Cancer. 1985 Academic Article GET IT
Times cited: 5
Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 29
Phase I-II trial of mitoxantrone in acute leukemia. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 53
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. Medical and pediatric oncology. 1984 Academic Article GET IT
Times cited: 6
Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. Medical and pediatric oncology. 1983 Academic Article GET IT
Times cited: 2
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer. 1982 Academic Article GET IT
Times cited: 11
Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Annals of internal medicine. 1982 Academic Article GET IT
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood. 1980 Academic Article GET IT
Times cited: 69
Splenectomy in chronic myeloid leukemia. Annals of internal medicine. 1978 Academic Article GET IT
Times cited: 24
Morbidity of staging laparotomy in Hodgkin's disease. The American journal of medicine. 1978 Academic Article GET IT
Times cited: 23
High dose methotrexate with citrovorum factor in adult resistant lymphoma. Cancer. 1977 Academic Article GET IT
Times cited: 13
Piperazinedione in metastatic renal carcinoma. Cancer treatment reports. 1977 Academic Article GET IT
Times cited: 4
A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Academic Article GET IT
Times cited: 26
Value of biopsy in diagnosis of primary lymphosarcoma of marrow. Archives of internal medicine. 1977 Academic Article GET IT
Times cited: 2
Peritoneoscopy in Hodgkin disease. Confirmation of results by laparotomy. JAMA. 1976 Academic Article GET IT
Times cited: 35
A clinical study of the lupus anticoagulant. Blood. 1976 Academic Article GET IT
Times cited: 404
Case report. Clostridium perfringens septicemia with detection of phospholipase C activity in the serum. The American journal of the medical sciences. 1976 Academic Article GET IT
Times cited: 5
The bone marrow in polycythemia vera. Seminars in hematology. 1975 Academic Article GET IT
Times cited: 60
Diagnosis of plasma cell myeloma. American family physician. 1975 Academic Article GET IT
The chemotherapy of plasma cell myeloma and related disorders. Antibiotics and chemotherapy. 1974 Information Resource GET IT
Times cited: 10
The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow and liver needle biopsy. Journal of chronic diseases. 1973 Academic Article GET IT
Times cited: 33
The staging of Hodgkin's disease. Selective vs routine laparotomy. JAMA. 1973 Academic Article GET IT
Times cited: 11
Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood. 1972 Academic Article GET IT
Times cited: 72

VIVO Weill Cornell Medical College

Morton Coleman Clinical Professor of Medicine

Publications

selected publications

Contact

full name

primary email

webpage